Member Exclusive

New funding will support development of personalized cell therapies for compromised patient populations

A Biomedical Catalyst Primer Award will fund research into low transfection efficient in patients with already highly compromised cell populations.

Go to the profile of Freya Leask
Oct 10, 2017
0
0

Please sign in or register for FREE

No comments yet.